CoChat

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors

Open access
Gonzalez-Cao, Maria, Mayo-de-las-Casas, Clara, Molina-Vila, Miguel A., De Mattos-Arruda, Leticia, Muñoz-Couselo, Eva, Manzano, Jose L., Cortes, Javier, Berros, Jose P., Drozdowskyj, Ana, Sanmamed, Miguel, Gonzalez, Alvaro, Alvarez, Carlos, Viteri, Santiago, Karachaliou, Niki, Martin Algarra, Salvador, Bertran-Alamillo, Jordi, Jordana-Ariza, Nuria, Rosell, Rafael · 2015 · Melanoma Research
Cited by 79

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BRAFV600E is a unique molecular marker for metastatic melanoma, being the most frequent somatic point mutation in this malignancy. Detection of BRAFV600E in blood could have prognostic and predictive value and could be useful for monitoring response to BRAF-targeted therapy. We developed a rapid, sensitive method for the detection and quantification of BRAFV600E in circulating free DNA (cfDNA) isolated from plasma and serum on the basis of a quantitative 5'-nuclease PCR (Taqman) in the presence of a peptide-nucleic acid. We validated the assay in 92 lung, colon, and melanoma archival serum and plasma samples with paired tumor tissue (40 wild-type and 52 BRAFV600E). The correlation of cfDNA BRAFV600E with clinical parameters was further explored in 22 metastatic melanoma patients treated with BRAF inhibitors. Our assay could detect and quantify BRAFV600E in mixed samples with as little as 0.005% mutant DNA (copy number ratio 1 : 20 000), with a specificity of 100% and a sensitivity of 57.7% in archival serum and plasma samples. In 22 melanoma patients treated with BRAF inhibitors, the median progression-free survival was 3.6 months for those showing BRAFV600E in pretreatment cfDNA compared with 13.4 months for those in whom the mutation was not detected (P=0.021). Moreover, the median overall survival for positive versus negative BRAFV600E tests in pretreatment cfDNA differed significantly (7 vs. 21.8 months, P=0.017). This finding indicates that the sensitive detection and accurate quantification of low-abundance BRAFV600E alleles in cfDNA using our assay can be useful for predicting treatment outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/cmr.0000000000000187

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 79

Metadata

Authors
Gonzalez-Cao, M., Mayo-de-las-Casas, C., Molina-Vila, M. A., De Mattos-Arruda, L., Muñoz-Couselo, E., Manzano, J. L., Cortes, J., Berros, J. P., Drozdowskyj, A., Sanmamed, M., Gonzalez, A., Alvarez, C., Viteri, S., Karachaliou, N., Martin Algarra, S., Bertran-Alamillo, J., Jordana-Ariza, N., & Rosell, R.
Venue
Melanoma Research
Published
2015-12
Volume
25
Issue
6
Pages
486-495
ISSN
0960-8931 (ISSN-L)
OpenAlex
W2418361789
Cited by
79
References
6
FWCI
4.25
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. https://app.cochat.ai/papers/10.1097/cmr.0000000000000187
The paper
Gonzalez-Cao, M., Mayo-de-las-Casas, C., Molina-Vila, M. A., De Mattos-Arruda, L., Muñoz-Couselo, E., Manzano, J. L., Cortes, J., Berros, J. P., Drozdowskyj, A., Sanmamed, M., Gonzalez, A., Alvarez, C., Viteri, S., Karachaliou, N., Martin Algarra, S., Bertran-Alamillo, J., Jordana-Ariza, N., & Rosell, R. (2015). BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Research. https://doi.org/10.1097/cmr.0000000000000187

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.